Bliss GVS Pharma Ltd Stock Analysis

BSE: 506197 | NSE: BLISSGVS | Pharmaceuticals & Drugs | Small Cap

BSE Share Price 09-Dec-2022 10:45
74.10 -0.15 (-0.20%)

DeciZen - Make an Informed Decision on Bliss GVS Pharma

Overall Rating

1. Quality

2. Valuation

Somewhat Undervalued

3. Price Trend

Bliss GVS Pharma Price Chart

P/E Ratio (SA) :
8.02
Market Cap :
773.3 Cr.
52-wk low :
66.3
52-wk high :
118.9
Bole Toh?

1. Is Bliss GVS Pharma Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Bliss GVS Pharma Ltd is a below average quality company.

2. Is Bliss GVS Pharma Ltd undervalued or overvalued?

The key valuation ratios of Bliss GVS Pharma Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

3. Is Bliss GVS Pharma Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Bliss GVS Pharma Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Bliss GVS Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Bliss GVS Pharma Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
ROCE % 19.9%12.4%14%13.4%12.2%9.7%8.8%10.6%8.2%9%-
Value Creation Index 0.4-0.1-0-0.0-0.1-0.3-0.4-0.3-0.4-0.4-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 354288313326348298427442466636615
YoY Gr. Rt. %--18.5%8.6%4.3%6.6%-14.4%43.2%3.6%5.3%36.7%-
Adj EPS 4.93.85.15.45.85.25.4767.59.3
YoY Gr. Rt. %--21.8%32.9%6.9%6.9%-10.8%4.3%29.6%-13.2%23.3%-
BVPS (₹) 24.930.435.741.947.752.558.566.272.381.286.5
Adj Net Profit 50.239.252.155.759.553.255.371.862.377.396
Cash Flow from Ops. -51.964.715.459.638.522.748.363.267114-
Debt/CF from Ops. -1.51.35.91.424.11.51.41.30.8-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 6.7%12.8%14.3%36.7%
Adj EPS 4.9%5.2%11.5%23.3%
BVPS 14.111.211.512.2
Share Price 6.5% -18.3% -21.8% -28.2%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
Return on Equity % 21.413.715.313.912.910.39.711.28.79.611
Op. Profit Mgn % 28.522.927.629.62929.722.422.719.717.215.7
Net Profit Mgn % 14.213.616.717.117.117.91316.213.412.115.7
Debt to Equity 0.30.30.20.20.20.20.10.10.10.10
Working Cap Days 270508497527533621442443471372477
Cash Conv. Cycle 100144154206206270269307293212394

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 11.00%

Sales growth is growing at healthy rate in last 3 years 14.26%

Net Profit is growing at healthy rate in last 3 years 11.53%

Sales growth is good in last 4 quarters at 17.83%

No data to display

Latest Financials - Bliss GVS Pharma Ltd.

Standalone Consolidated
TTM EPS (₹) 9.3 0.9
TTM Sales (₹ Cr.) 615 744
BVPS (₹.) 86.5 82.1
Reserves (₹ Cr.) 891 844
P/BV 0.86 0.90
PE 8.02 85.05
From the Market
52 Week Low / High (₹) 66.25 / 118.90
All Time Low / High (₹) 0.04 / 230.00
Market Cap (₹ Cr.) 773
Equity (₹ Cr.) 10.4
Face Value (₹) 1
Industry PE 37

Management X-Ray of Bliss GVS Pharma :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.330.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Bliss GVS Pharma

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)

News

Bliss GVS Pharma Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Bliss GVS Pharma on 09-Dec-2022 10:45 is : 74.10.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 09-Dec-2022 10:45 the market cap of Bliss GVS Pharma stood at ₹ 773.3.
The latest PE ratio of Bliss GVS Pharma as of 09-Dec-2022 10:45 is 8.02.
The latest PB ratio of Bliss GVS Pharma as of 09-Dec-2022 10:45 is 0.86
The 52-week high of Bliss GVS Pharma is ₹ 118.9 and the 52-week low is ₹ 66.25.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Bliss GVS Pharma is ₹ 615.0 ( Cr.) .

About Bliss GVS Pharma Ltd

Bliss Gvs Pharma Limited was incorporated on December 11, 1984, as Public Limited Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company has established a foothold in various therapeutic categories including anti-malarial, anti-fungal, contraceptive, laxative, anti-haemorrhoidal, anti-spasmodic, anti-biotic, anti-microbial, antiinflammatory, anti-pyretic, analgesic, and several others.

It is among the world leaders in Suppositories and Pessaries dosage forms with one of the largest portfolios in this segment. Over the last decade, it has acquired definitive know-how in other dosage forms & therapeutic segments, which is exemplified by its ever-expanding product offering across more than sixty countries. With significant expansion in R & D, Manufacturing & Marketing capabilities, the company is poised for an accelerated rate of growth which makes for very exciting times at Bliss GVS.

Business area of the company

It is a fast-growing Pharmaceutical Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company’s most unique product is ‘Today Vaginal Contraceptive’, a safe female contraceptive aimed at furthering Planned Parenthood and is also an established method for preventing conception. Bliss also manufactures to US specification vaginal pessaries of Clotrimazole & Povidone Iodine in addition to Anal Suppositories for treatment of piles. The company also manufacture wide range of Pessary Formulations, Suppository Formulations, Calcium Preparation, Protein Powders, Iron Preparation, Antibiotics, Analgesic & Antipyretics, Respiratory, Anti-inflammatory, Dermatological Preparations, Anti-Diarrhoeal products.

Key Milestones

  • 1984: Incorporated as Bliss Chemicals and Pharmaceuticals Limited.
  • 1986: Launch of Flagship product ‘TODAY’, a vaginal contraceptive.
  • 2006: Merger of GVS Labs with Bliss Chemicals & Pharma to form Bliss GVS Pharma Ltd.
  • 2007: Commissioning of manufacturing units for Tablets & Dry Syrups at Palghar.
  • 2010: Commissioning of a state-of-the-artfacility for Suppositories and Pessaries.
  • 2011: EU-GMP approval to the manufacturing facility for suppository facility.
  • 2015: Setting up Healthcare Centres in East Africa under Bliss GVS Healthcare.
  • 2017: Setting up offices in South East Asian countries.
  • 2018: Divestment from Bliss GVS Healthcare.
  • 2019: Setting up of multi-dosage facility (Vevoor Plant).
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now